ArticleCureus2025
Silicone Oil Droplets in the Vitreous After an Anti-vascular Endothelial Growth Factor (VEGF) Injection: A Complication of Syringe Lubrication.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.Cell death discovery · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intravitreal anti-vascular endothelial growth factor (VEGF) injections are a cornerstone treatment for various retinal conditions, including diabetic macular edema and age-related macular degeneration. While generally safe, these injections can introduce unintended substances, such as silicone oil droplets, into the vitreous cavity due to the silicone-based lubricant used in syringe manufacturing. Although frequently asymptomatic, silicone oil droplets can occasionally cause significant visual disturbances and discomfort. We report a rare case of symptoms caused by silicone oil droplets following a single intravitreal bevacizumab injection. A 54-year-old diabetic male patient presented with pain and iridescent floaters in his right eye, which began immediately after receiving an intravitreal bevacizumab injection and persisted for four weeks. The patient, with a 20-year history of diabetes and prior scatter laser photocoagulation, exhibited a visual acuity of 20/80 in the right eye or oculus dexter (OD) and 20/40 in the left eye or oculus sinister (OS), with an elevated intraocular pressure (IOP) of 24 mmHg in the right eye. Dilated fundoscopy revealed multiple silicone oil droplets floating in the vitreous cavity, alongside severe non-proliferative diabetic retinopathy and macular edema. The patient was started on anti-glaucoma medications, brimonidine, and timolol, which effectively reduced his IOP to 18 mmHg within a week. Despite IOP control, the patient remained distressed by persistent floaters, which gradually became less symptomatic with time. This case is unique because the symptoms due to the silicone oil droplets occurred after a single injection, unlike most reports of asymptomatic presentations or those arising after multiple injections. The disproportionate amount of silicone oil observed raises concerns about syringe design and transport conditions. While silicone oil is inert, its presence can cause the patient anxiety and visual disturbances.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.